Danish biotech company Synact Pharma, which went public in Sweden in 2016, has applied for permission from Danish Medicines Agency and the National Committee on Health Research Ethics to initiate a larger phase II study with AP1189 - the company's candidate for treatment of rheumatoid arthritis.
"Our goal was to take AP1189 to phase II of the clinical development, so this is an important milestone for the company, which we have worked towards for most of 2018," says Jeppe Øvlesen, CEO in Synact Pharma, to MedWatch.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.